John Paul Blass

Last updated

John P. Blass, physician, biochemist and neurochemist, was born on February 21, 1937 in Vienna, Austria, and deceased March 12, 2023 in New York City. Both his parents were physicians; his father, Gustaf Blass, was a prominent Viennese radiologist and his mother, Jolan Wirth Blass, a student of Sigmund Freud, was a psychoanalyst originally from Budapest. The family then moved to Stamford, Connecticut. Both parents practiced psychiatry, Gustaf in a private sanitarium in Stamford and Jolan as a child psychiatrist in New York City and Connecticut.[ citation needed ] He is survived by his wife, son and two granddaughters.

Contents

Blass's most prominent professional achievements were in the area of aging and Alzheimer's disease, in particular relating to brain metabolism. He was granted patents based on decades of scientific research, including a neutraceutical "metabolic enhancer" which has been under study in a large-scale, controlled, "multicenter" clinical trial.

He wrote and contributed to a number of books including assorted volumes on Alzheimer's disease and a textbook on pharmacology.

Education and institutional positions

Dr. Blass's studies brought him to Harvard College (summa cum laude, class of 1958, Harvard Scholar, Phi Beta Kappa (senior sixteen), Sigma Xi, Biochemical Sciences major); the University of London where as a Marshall Scholar he earned his PhD in Biochemistry (1960) under thesis professor and pioneer of modern neurochemistry Henry McIlwain; and to Columbia College of Physicians and Surgeons where Blass earned his medical degree (Alpha Omega Alpha, class of 1965). During this time, he took a year off to do research as an American Cancer Society fellow in the laboratory of Dr. Heinrich Waelsch, another founding father of neurochemistry. Dr. Blass's internship and residency was in internal medicine at the Massachusetts General Hospital in Boston (1965–67). He then spent three years (1967-1970) in the National Heart Institute at the National Institute of Health (NIH)(now the National Heart, Lung, and Blood Institute (NHLBI). From 1970-1978 he was Assistant and Associate Professor of Psychiatry and Biochemistry at the UCLA Neuropsychiatric Institute. In 1978 he was appointed Winifred Masterson Burke Professor of Neurology and Medicine at Weill Medical College of Cornell University. Dr. Blass established and directed the Dementia Research Service, a combined research and clinical unit at a Cornell-affiliated institution, the Burke Medical Research Institute. He was also appointed in the field of Neurosciences. He served on the National Panel on Alzheimer's Disease from 1986 to 1996 and was its Chairman from 1986 to 1991. As a member of the National Institute on Aging, he was Chairman of Geriatric Medicine Ad Hoc Review Committees from 1981 to 1984, and Chairman of the Consensus Panel on Neurochemistry of Alzheimer's Disease in 1982. He served on the President's Department of Health and Human Services Task Force on Alzheimer's Disease in 1982-1984. He was President of the American Federation for Aging Research in 1994-1996. In 2005, he became Emeritus Professor at Cornell, and fully retired as of 2007. [ citation needed ]

In September 2007, the New York Academy of Sciences held a conference in honor of Dr. Blass, 'Mitochondria and Oxidative Stress in Neurodegenerative Disorders', also a satellite meeting of the International Society of Neurochemistry. [1]

Also in 2007 the scientific journal Neurochemical Research published a special issue (Volume 32, Numbers 4-5, 775-781, doi : 10.1007/s11064-006-9207-7) dedicated to Dr. Blass. [2]

Publications

Among Dr. Blass's roughly 200-250 publications, his papers in the New England Journal of Medicine are the most widely recognized, e.g. 'Abnormality of a thiamine-requiring enzyme in patients with Wernicke–Korsakoff syndrome' (New Eng J Med 1977; 297: 1367-1370, with Gary E. Gibson). [3]

Dr. Blass was author of the textbook 'Concise Clinical Pharmacology: CNS Therapeutics' (2006, McGraw-Hill Education, ISBN   0-07-144036-4 (0-07-144036-4)); and co-author of Alzheimer's Disease: A Physician's Guide to Practical Management (with Ralph W. Richter, 2003, Humana Press, ISBN   0-89603-891-2 (0-89603-891-2)), Oxidative/Energy Metabolism in Neurodegenerative Disorders (with Fletcher H. McDowell, 1999, New York Academy of Sciences, ISBN   1-57331-209-6 (1-57331-209-6)), Alzheimer's Disease Vol. 1: New Treatment Strategies (with Zhaven Khachaturian, 1992, Dekker Incorporated, Marcel, ISBN   0-8247-8620-3 (0-8247-8620-3)), Caring for Alzheimer's Patients: A Guide for Family and Healthcare Providers (with Ralph W. Richter, 1989, Insight Productions, ISBN   0-306-43199-8 (0-306-43199-8)), and Principles of Geriatric Medicine and Gerontology (with Fletcher H. McDowell, 1989, McGraw-Hill Education, ISBN   0-07-027500-9 (0-07-027500-9) plus multiple subsequent editions with additional authors).

Board, council, and society memberships

Dr. Blass served on the editorial boards of 17 journals including the Journal of Neurochemistry. He was associate editor of the Journal of the American Geriatrics Society for five years. He served on a number of governmental review panels and other committees, including the Council of the National Institute on Aging. He was the first chair of the joint Presidential-Congressional Panel on Alzheimer's Disease and Related Disorders. Blass consulted for state governments and for private foundations in the US and Europe. He was a past president of the American Federation of Aging Research, [4] and remained on its board since its founding. His academic honors include several visiting professorships. He served as a member of the council of both the American Society for Neurochemistry and the International Society for Neurochemistry. He belonged to a number of other scholarly societies, including the American Society for Clinical Investigation, the American Society of Biochemistry and Molecular Biology (http://www.asbmb.org/), Phi Beta Kappa, [5] Sigma Xi, [6] and Alpha Omega Alpha. [7]

Research, laboratory focus, and projects

Regarding his research, in 2005 Dr. Blass wrote: "One of the things that happens in Alzheimer's disease and a number of other neurological diseases is a decrease in the brain's ability to burn its fuels with the usual speed and efficiency. My laboratory was particularly interested in diseases affecting the brain's ability to burn its major fuel, sugar. These diseases affect the power plants of the cell (mitochondria) and specifically a part of the mitochondria, namely the Krebs tricarboxylic acid cycle. My coworkers and I were among the first researchers to study the abnormalities in mitochondria in the Alzheimer brain. Our discoveries led me to develop a patented nutraceutical preparation that appeared to slow or stop the progression of Alzheimer's disease, in a small but rigorous study. As emeritus professor, my current focus is further development and clinical testing of this and related preparations designed to help people with Alzheimer disease and other diseases that cause degeneration of the brain."

Dr. Blass's research concentrated on brain metabolism and metabolic diseases of the brain, particularly diseases affecting the mitochondria and specifically the Krebs tricarboxylic acid cycle. Blass's interest in this topic began at NIH, where he described the first hereditary defect in a major enzyme of human oxidative/energy metabolism, pyruvate dehydrogenase deficiency. Since moving to Cornell, his work concentrated on Alzheimer Disease and other neurodegenerative diseases. He and his coworkers pioneered the finding that inherent abnormalities of mitochondrial components occur in Alzheimer brain and other Alzheimer tissues and the implications of that finding for the pathophysiology of the dementia. He also published on clinical aspects of Alzheimer's disease and other causes of cognitive impairment.

In his later years, Dr. Blass was involved in developing a nutraceutical "metabolic enhancer" which appeared to slow the progression of Alzheimer's disease and related disorders in a relatively small placebo-controlled clinical trials and is under study in a larger multicenter trial. Cornell devolved the patent for this invention on him.

Related Research Articles

Neurochemistry is the study of chemicals, including neurotransmitters and other molecules such as psychopharmaceuticals and neuropeptides, that control and influence the physiology of the nervous system. This particular field within neuroscience examines how neurochemicals influence the operation of neurons, synapses, and neural networks. Neurochemists analyze the biochemistry and molecular biology of organic compounds in the nervous system, and their roles in such neural processes including cortical plasticity, neurogenesis, and neural differentiation.

The oxoglutarate dehydrogenase complex (OGDC) or α-ketoglutarate dehydrogenase complex is an enzyme complex, most commonly known for its role in the citric acid cycle.

<span class="mw-page-title-main">Neurodegenerative disease</span> Central nervous system disease

A neurodegenerative disease is caused by the progressive loss of structure or function of neurons, in the process known as neurodegeneration. Such neuronal damage may ultimately involve cell death. Neurodegenerative diseases include amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, multiple system atrophy, and prion diseases. Neurodegeneration can be found in the brain at many different levels of neuronal circuitry, ranging from molecular to systemic. Because there is no known way to reverse the progressive degeneration of neurons, these diseases are considered to be incurable; however research has shown that the two major contributing factors to neurodegeneration are oxidative stress and inflammation. Biomedical research has revealed many similarities between these diseases at the subcellular level, including atypical protein assemblies and induced cell death. These similarities suggest that therapeutic advances against one neurodegenerative disease might ameliorate other diseases as well.

<span class="mw-page-title-main">Brain mitochondrial carrier protein 1</span> Protein-coding gene in the species Homo sapiens

Brain mitochondrial carrier protein 1 is a protein that in humans is encoded by the SLC25A14 gene.

Peter Riederer is a German neuroscientist with several thousands of citations and around 950 scientific writings. He has published more than 620 scientific papers in peer-reviewed scientific journals that are indexed in Medline. He has been author and co-author of more than 20 books relevant to the fields of neuroscience, psychiatry and neurology.

<span class="mw-page-title-main">GTS-21</span> Chemical compound

GTS-21 is an investigational drug that has been studied for its potential therapeutic uses, particularly in the treatment of neurodegenerative diseases and psychiatric disorders.

John Quinn Trojanowski was an American academic research neuroscientist specializing in neurodegeneration. He and his partner, Virginia Man-Yee Lee, MBA, Ph.D., are noted for identifying the roles of three proteins in neurodegenerative diseases: tau in Alzheimer's disease, alpha-synuclein in Parkinson's disease, and TDP-43 in Amyotrophic Lateral Sclerosis (ALS) and frontotemporal degeneration.

<span class="mw-page-title-main">Judes Poirier</span>

Judes Poirier is Canadian-born professor of Medicine and Psychiatry at McGill University and former director of the Centre for Studies in Aging at McGill University. He currently serves as director of the Molecular Neurobiology Unit at the Douglas Institute Research Centre and, co-founder and associate director of the Centre for the Studies on the Prevention of Alzheimer's disease at McGill University.

<span class="mw-page-title-main">Michel Goedert</span> Luxembourgish-British neuroscientist

Michel Goedert FRS, FMedSci is a Luxembourgish-British neuroscientist and former Head of Neurobiology, at the MRC Laboratory of Molecular Biology.

<span class="mw-page-title-main">Moussa B. H. Youdim</span>

Moussa B. H. Youdim is an internationally renowned Israeli neuroscientist specializing in neurochemistry and neuropharmacology. He is the discoverer of both monoamine oxidase (MAO) B inhibitors l-deprenyl (Selegiline) and rasagiline (Azilect) as anti-Parkinson drugs which possess neuroprotective activities. He is currently Professor Emeritus at Technion - Faculty of Medicine and President of Youdim Pharmaceuticals.

<span class="mw-page-title-main">Suh Yoo-hun</span>

Suh Yoo-hun is a South Korean neuroscientist. His researches focus on neurodegeneration, especially on the discovery of genes and therapies for Alzheimer's disease and Parkinson's disease.

<span class="mw-page-title-main">Svetlana Dambinova</span> Russian neuroscientist

Svetlana Dambinova is a Russian neuroscientist, Doctor of Biological Sciences, Distinguished Professor at Laboratory of biomarkers at Medical Center "DeKalb", Atlanta, USA. Dambinova was awarded as Honored Worker of Science of the Republic of Buryatia (1996) and Russian Federation (1998). Known in the world for research of glutamate receptors. The Head of the project of the International Department of Neurology SPBGMU them. Acad. Pavlov's.

<span class="mw-page-title-main">Rajiv Ratan</span> American physician

Rajiv Ratan is an Indian American academic, professor, administrator and scientist based in New York. He is the Burke Professor of Neurology and Neuroscience at Weill Cornell Medicine. Since 2003, he has served as the executive director of Burke Neurological Institute and as a member of the Council of Affiliated Deans of Weill Cornell Medicine.

Kochupurackal P. Mohanakumar is an Indian chemical biologist, neuroscientist and the director of Inter University Centre for Biomedical Research and Super Specialty Hospital, Kottayam. He is a former chief scientist at the Indian Institute of Chemical Biology and is known for his studies on Parkinson's disease and Huntington’s disease. The Department of Biotechnology of the Government of India awarded him the National Bioscience Award for Career Development, one of the highest Indian science awards, for his contributions to biosciences in 2000.

Donald L. Price is an American neuropathologist and professor at the Johns Hopkins School of Medicine born in Stamford, Connecticut. His research aims to understand the molecular basis of neurodegenerative diseases, particularly Alzheimer’s disease. Price has received a number of awards for his work and served as the President of both the American Association of Neuropathologists and the Society for Neuroscience.

Lary Walker is an American neuroscientist and researcher at Emory University in Atlanta, Georgia. He is Associate Director of the Goizueta Alzheimer's Disease Research Center at Emory, and he is known for his research on the role of abnormal proteins in the causation of Alzheimer’s disease.

Henrik Zetterberg is a Swedish professor of neurochemistry at the University of Gothenburg, where he is the Head of the Department of Neurochemical Pathophysiology and Diagnostics. He is also the leader of the Fluid biomarkers for Neurodegenerative Diseases group at University College London. The groups work on developing early tests for dementia.

<span class="mw-page-title-main">Rolf Gruetter</span> Swiss physicist specialized in magnetic resonance

Rolf Gruetter is a Swiss physicist and neurobiologist specialized in magnetic resonance, biomedical imaging and brain metabolism. He is a professor of physics at EPFL and the head of the Laboratory Functional and Metabolic Imaging at the School of Basic Sciences.

Ana Cristina Rego is a Portuguese neurologist. She is a professor at the University of Coimbra in Portugal and is head of the research group on Mitochondria and Neurodegenerative disorders, researching on topics such as Alzheimer’s disease, Huntingdon's disease, and Parkinson’s disease. She is presently president of the Portuguese Society of Neuroscience.

<span class="mw-page-title-main">Juan Pedro Bolaños</span> Spanish researcher

Juan Pedro Bolaños Hernández is a biochemist and neuroscientist specializing in neuroenergetics and metabolism. He is a professor of Biochemistry and Molecular Biology at the University of Salamanca. His investigation focuses on the understanding of molecular mechanisms that regulate the metabolism and redox homeostasis in the cells of the central nervous system. He has received several recognitions throughout his scientific career. Among them is the Premio Castilla y León de Investigación Científica y Técnica e Innovación.

References

  1. ↑ http://www.nyas.org/Events/Detail.aspx?cid=8a0f4c49-b1c2-46d1-bc05-68984e789335 http://www.nyas.org/Publications/EBriefings/Detail.aspx?cid=43761f39-1397-4cfb-b1ef-43f864ac5fbb
  2. ↑ Luchsinger, J. A.; Tang, M. X.; Miller, J.; Green, R.; Mehta, P. D.; Mayeux, R. (2007). "[Keywords: Homocysteine - Plasma - Amyloid beta - Alzheimer's disease". Neurochemical Research. 32 (4–5): 775–781. doi:10.1007/s11064-006-9207-7. PMID   17191133.
  3. ↑ 'Glucose Mitochondria in Neurological Conditions' (International Review of Neurobiology, 2002, http://www.cingulate.ibms.sinica.edu.tw/Ftpshare/Protocol/Internet%20Resources/E%20books/glucose%20metabolism%20in%20the%20brain/8.pdf%5B%5D)
  4. ↑ "American Federation for Aging Research: welcome". Afar.org. Retrieved 2012-02-21.
  5. ↑ "Phi Beta Kappa Society:: Home". Pbk.org. 2012-01-21. Retrieved 2012-02-21.
  6. ↑ "Sigma Xi, The Scientific Research Society". Sigmaxi.org. 2011-02-05. Retrieved 2012-02-21.
  7. ↑ "Alpha Omega Alpha Honor Medical Society". Alphaomegaalpha.org. 2009-04-14. Retrieved 2012-02-21.

Conversations with Dr. Blass

CV including List of Publications: https://web.archive.org/web/20160304040159/http://www.johnblass.org/JohnPBlass_CV.pdf

Burke Medical Research Institute (http://www.burke.org/)

Weill Medical College of Cornell University (http://www.med.cornell.edu/)

New York Academy of Sciences conference in honor of Dr. Blass, 'Mitochondria and Oxidative Stress in Neurodegenerative Disorders' http://www.nyas.org/Events/Detail.aspx?cid=8a0f4c49-b1c2-46d1-bc05-68984e789335

Neurochemical Research special issue dedicated to Dr. Blass https://doi.org/10.1007%2Fs11064-006-9207-7

Obituary, New York Times/ Legacy.com: https://www.legacy.com/us/obituaries/nytimes/name/john-blass-obituary?id=51253816

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.